European Union Approves Victrelis for Chronic Hep C
VICTRELIS(TM) (boceprevir), First-in-Class Oral Hepatitis C Virus Protease Inhibitor, Approved in the European Union for Treatment of Chronic Hepatitis C
WHITEHOUSE STATION, N.J., Jul 18, 2011 (BUSINESS WIRE) — Merck MRK -0.64% , known as MSD outside the United States and Canada, today announced that the European Commission (EC) has approved VICTRELIS(TM)(boceprevir) for the treatment of chronic hepatitis C (CHC) genotype 1 infection, in combination with peginterferon alfa and ribavirin, in adult patients with compensated liver disease who are previously untreated or who have failed previous therapy. Chronic hepatitis C virus (HCV) is a potentially serious viral infection of the liver that affects an estimated 4 million people in Europe.
The European Commission’s Decision grants a single marketing authorisation that is valid in the 27 countries that are members of the European Union (EU), as well as unified labeling applicable to the European Economic Area members, Iceland, Liechtenstein and Norway.
Continue reading this entire article: